Group One Trading
STRO icon

Group One Trading’s Sutro Biopharma STRO Stock Holding History

Group One Trading’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-120
Closed -$4.15K – 7942
2024
Q3 		$4.15K Hold
120
– – ﹤0.01% 5947
2024
Q2 		$3.52K Buy
+120
New +$4.75K ﹤0.01% 6084

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Group One Trading's STRO Position: Q1 2026 in Review

Group One Trading sold out of Sutro Biopharma (STRO) in Q1 2026, closing a stake of 2 shares — an estimated $23 sold.

Group One Trading first reported a position in STRO in Q4 2020 and held it in 12 quarters. The position peaked at $209K in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Group One Trading reported no remaining Sutro Biopharma position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 2 Sutro Biopharma shares in Q1 2026, an estimated $23.
  • Group One Trading first reported a position in Sutro Biopharma in Q4 2020 and held it in 12 quarters.
  • Group One Trading's Sutro Biopharma position peaked at $209K in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.